About

Richard Lalonde is currently an adjunct professor in the Center for Pharmacometrics and Systems Pharmacology in the Department of Pharmaceutics at the University of Florida College of Pharmacy, and a consultant to the pharmaceutical industry. He was previously at Pfizer for 19 years and served as Vice President and Global Head of Clinical Pharmacology for the last 11 years of his tenure, until he retired in 2017. Prior to joining Pfizer via the merger with the Warner Lambert organization, he was Scientific Director and Head of Clinical Pharmacology and Pharmacokinetics at Phoenix International in Montreal from 1991 to 1998. From 1984 to 1991 he was Assistant Professor and then a tenured Associate Professor and Vice Chair for Research in the Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis. He also worked from 1980 to 1984 at the University of Ottawa Health Sciences Centre. Richard is a Fellow of the American College of Clinical Pharmacology, the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacy. He was President of the American Society for Clinical Pharmacology and Therapeutics (2011 – 2012), a member of its Board of Directors (2010-2013) and in 2017 received the Gary Neil Prize for Innovation in Drug Development from ASCPT. Richard also received the International Society of Pharmacometrics Leadership Award in 2014. From 2004 – 2009 he served on the Board of Regents of the American College of Clinical Pharmacology. He has been a member of the editorial board of Clinical Pharmacology and Therapeutics since 2005 (Associate Editor 2007-2010) and was a member of the editorial board of Pharmaceutical Research from 1998 – 2001. He served on the National Advisory General Medical Sciences Council at the National Institutes of Health, Bethesda, MD from 2013 – 2016. Richard has been an invited speaker at various national and international meetings of professional societies, universities, and governmental/regulatory agencies in the US (FDA & NIH), Europe (EMA), Japan (PMDA) and China (CFDA). Over the past 39 years, his work has been focused on the quantitative application of pharmacokinetic and pharmacodynamic principles to the optimal development and utilization of new drugs in patients.

Research topics

• Biology
• Business
• Economic growth
• Economics

Selected publications

• How debunking biases in research and development decisions could lead to more equitable healthcare?

  Clinical and Translational Science · 2024 · 2 citations

  • Business
  • Economics
  • Biology

  Decades of research have demonstrated that a variety of cognitive biases can affect our judgment and ability to make rational decisions in personal and professional environments. The lengthy, risky, and costly nature of pharmaceutical research and development (R&D) makes it vulnerable to biased decision-making. Moreover, cognitive biases can play a role in regulatory and clinical decision-making, the latter impacting diagnostic and treatment decisions in the therapeutic use of medicines. These inherent and/or institutionalized biases (e.g., in assumptions, data, or decision-making practices) could conceivably contribute to health inequities. In this mini-review, we provide a broad perspective on how cognitive biases can affect pharmaceutical R&D, regulatory evaluation, and therapeutic decision-making. Example approaches to mitigate the effect of common biases in the development, approval, and use of new therapeutics, such as quantitative decision criteria, multidisciplinary reviews, regulatory and treatment guidelines, and evidence-based clinical decision support systems are illustrated. Mitigating the impact of cognitive biases could increase pharma R&D efficiency, change the perspective and prioritization of unmet medical needs, increase representativeness and quality of evidence generated through clinical trials and real-world research, leading to higher quality insights and more effective medication use, and as such could eventually contribute to more equitable healthcare.

  DOI

Frequent coauthors

• Brian Corrigan

  Pfizer (United States)

  4 shared

• Diane Stephenson

  Critical Path Institute

  3 shared

• Hannu Peräkylä

  Turku PET Centre

  3 shared

• Jon Clardy

  Harvard University

  3 shared

• Kaori Ito

  Meijo University

  3 shared

• Linda S. Brinen

  3 shared

• Yoshihide Ishiguro

  3 shared

• Klaus Romero

  Critical Path Institute

  3 shared

Education

• Other

  University of Minnesota

• Other

  University of Toronto

Awards & honors

• Gary Neil Prize for Innovation in Drug Development from ASCP…
• International Society of Pharmacometrics Leadership Award (2…

Similar researchers at University of Florida

• Steven T DeKoskyh-162
• Matthew Farrerh-133
• George Christouh-133
• Mark A Atkinsonh-129
• Christiaan Leeuwenburghh-125